Reports and Briefs on Pharmaceuticals and Healthcare in Asia-Pacific

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Report
Report

Commercial Insight: Asthma/COPD in Australia

In-depth overview and 10 year outlook for currently marketed and pipeline asthma/COPD products in Australia, examining both clinical and commercial factors driving product differentiation and uptake.

Published By Datamonitor
20 May 2010 $5700
Buy
Report
Report

Commercial Insight: Disease Modification in Rheumatoid Arthritis – Market awaits game changing therapies and strategies

Coverage of disease-modifying drugs in the seven major rheumatoid arthritis markets, including indication-specific 10-year forecasts (using both sales and patient-based approaches), detailed brand profiling and an in-depth patient-based case study.

Published By Datamonitor
15 Dec 2010 $6400
Buy
Report
Report

Commercial Insight: Hepatitis B in China

Discussion of the Chinese hepatitis B market including epidemiology, market drivers, and strategic analysis of key players. Assessment of marketed and pipeline products. Commercial forecast of market size and product sales and volumes to 2019.

Published By Datamonitor
17 Feb 2011 $2800
Buy
Report
Report

Commercial Insight: Hormonal Contraceptives - Look beyond oral contraception for a competitive edge

Full analysis of the current and future hormonal contraceptives drug market, with country-specific forecasts to 2018 of marketed, generic, and key pipeline drugs in the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK).

Published By Datamonitor
02 Oct 2009 $15200
Buy
Report
Report

Commercial Insight: Inflammatory Bowel Disease - Future market prospects rely on addressing cost and safety

Coverage of the inflammatory bowel disease (IBD) market, including indication-specific 10-year forecasts, detailed brand profiling, opportunities and threats, and a scenario-based case study.

Published By Datamonitor
05 Aug 2010 $15200
Buy

Order this report by the 10th September 2010 and receive a 15% discount

To take advantage of this offer enter Promo Code opioid15 when prompted in the checkout

More information

Report
Report

Commercial Insight: Opioids in Australia

In-depth overview and 10 year outlook for currently marketed and pipeline opioid products in Australia, examining both clinical and commercial factors driving product differentiation and uptake.

Published By Datamonitor
20 May 2010 $5700
Buy
Report
Report

Commercial Insight: Osteoporosis - Market players maximize revenue growth before the next challenging phase

Comprehensive analysis of the current and future osteoporosis drug market, with country-specific forecasts to 2019 of marketed, generic, and key pipeline drugs in the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK).

Published By Datamonitor
21 Jul 2010 $15200
Buy
Report
Report

Delivery Across the Blood-Brain Barrier

CNS drugs are associated with longer development times and higher attrition rates than drugs for other therapy areas. Advances in delivery technologies are essential if the pursuit of novel treatments is to remain commercially viable.

Published By Datamonitor
05 Sep 2012 $2800
Buy
Report
Report

Drug Discovery for Rare Diseases

Favorable legislation and recent commercial successes have stimulated growing interest in the discovery of novel orphan drugs. However, there are many strategic considerations that are peculiar to the R&D process for diseases of low prevalence.

Published By Datamonitor
31 Aug 2012 $2800
Buy
Report
Report

Epidemiology of Hepatitis C in China

Urban migration and injection drug use patterns will continue to influence hepatitis C virus prevalence rates

Published By Datamonitor
03 Jan 2013 $2800
Buy

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.